This study aims to evaluate the effect of variantsin pharmacogenes SLC29A1, DCK, ABCB1, GSTM1and GSTT1, as well as laboratory and AML-relatedparameters on clinical outcome in adult AMLpatients. This evidence concerns the gene ABCB1 and acute myeloid leukemia.